Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

Clinical studies based on novel rationales and mechanisms of action of chemotherapy agents and cytokines can contribute to the development of new concepts and strategies of antitumor combination therapies. In previous studies, we investigated the paradoxical immunostimulating effects of some chemoth...

Full description

Bibliographic Details
Main Authors: Francesca Urbani, Virginia Ferraresi, Imerio Capone, Iole Macchia, Belinda Palermo, Carmen Nuzzo, Angela Torsello, Patrizio Pezzotti, Diana Giannarelli, Anna Fausta Pozzi, Mariano Santaquilani, Paolo Roazzi, Silvia Bastucci, Caterina Catricalà, Antonia La Malfa, Giuseppe Vercillo, Novella Gualtieri, Carla Buccione, Luciano Castiello, Francesco Cognetti, Paola Nisticò, Filippo Belardelli, Federica Moschella, Enrico Proietti
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
melanoma
combination therapy
chemotherapy
drug repurposing
interferon-α
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00202/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00202/full

Similar Items